Resource Type

Journal Article 12

Year

2023 1

2021 1

2019 2

2018 1

2015 1

2014 1

2013 1

2012 1

2009 2

2008 1

open ︾

Keywords

cirrhosis 4

hepatitis B 2

liver cirrhosis 2

N-glycan model 1

Alanine aminotransferase (ALT) level 1

Caesarean section 1

Chinese 1

Chronic hepatitis B 1

Decoction 1

Decoction intervention 1

Gastric endoscopy 1

Liver cirrhosis 1

Liver fibrosis 1

Microbiome 1

Serum N-glycan 1

Symptoms 1

Varices 1

acute liver failure (ALF) 1

angiotensin 1

angiotensin II 1

open ︾

Search scope:

排序: Display mode:

Correlation between viral load and liver cirrhosis in chronic hepatitis B patients

Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 271-276 doi: 10.1007/s11684-009-0054-1

Abstract: the relationship between hepatitis B virus (HBV) DNA levels during the course and the progression to cirrhosisCompared with the patients without cirrhosis, the patients progressed to cirrhosis were older and withHowever, there was no significant difference in cirrhosis progression between different HBV-DNA groupsKaplan-Meier analysis showed higher HBV-DNA level at endpoint had increasing risk of cirrhosis ( = 0.019Progression to cirrhosis in chronic hepatitis B patients is correlated with HBV-DNA levels during follow-up

Keywords: hepatitis B     chronic     viral load     liver cirrhosis    

Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis

Jiangyi Zhu, Yongquan Shi, Xinmin Zhou, Zengshan Li, Xiaofeng Huang, Zheyi Han, Jianhong Wang, Ruian Wang, Jie Ding, Kaichun Wu, Ying Han, Daiming Fan

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 255-263 doi: 10.1007/s11684-012-0227-1

Abstract:

The efficacy of ursodeoxycholic acid (UDCA) on long-term outcome of primary biliary cirrhosis (PBC

Keywords: primary biliary cirrhosis     ursodeoxycholic acid     Chinese     biochemical response     therapeutic efficacy    

Effects of Decoction on plasma proteome in cirrhosis: preliminary experimental study with rats

LIU Jie, WANG Jiyao, WEI Liming, LU Ye, Jin Hong

Frontiers of Medicine 2008, Volume 2, Issue 1,   Pages 39-44 doi: 10.1007/s11684-008-0008-z

Abstract: proteins related to oxidative stress, cell proliferation and transformation have changed in the plasma of cirrhosis

Keywords: Decoction intervention     serine/threonine-protein     underwent     Decoction     glutathione peroxidase    

Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated

Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 63-71 doi: 10.1007/s11684-014-0342-2

Abstract:

Cryoablation is a less prevalent percutaneous ablative therapy for hepatocellular carcinoma (HCC), and current evidence about its usefulness is limited. We report our experience in treating 1595 HCC cases with percutaneous cryoablation to give a comprehensive profile about the effectiveness, safety and long-term outcome of this therapy. From January 2003 to December 2013, 1595 patients with 2313 HCC nodules were ablated with 2945 cryoablation sessions in our center. Complete ablation was achieved in 1294 patients for 1893 nodules with a mean diameter of 3.4±2.2 cm. The complete ablation rate was 81.2%, 99.4%, 94.4%, and 45.6% in all tumors, tumors<3 cm, tumors<5 cm, and tumors>5 cm, respectively. Major complications were observed after 80 (3.4%) of the 2945 cryoablations and minor complications were observed after 330 cryoablations with no treatment-related deaths. After a median follow-up of 33.4 months, 937 patients developed different types of recurrence. The 5- and 10-year overall survival was 25.7% and 9.2%, respectively. Cryoablation showed reliable safety and efficacy and should be considered as a promising technique, particularly when a large zone of ablation is required.

Keywords: hepatocellular carcinoma     percutaneous cryoablation     efficacy     safety    

Assessment of liver volume variation to evaluate liver function

Cong Tong, Xinsen Xu, Chang Liu, Tianzheng Zhang, Kai Qu

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 421-427 doi: 10.1007/s11684-012-0223-5

Abstract:

In order to assess the value of liver volumetry in cirrhosis and acute liver failure (ALF) patientsThe clinical data of 48 cirrhosis patients with 60 normal controls and 39 ALF patients were collectedCTLV and SLV of all patients were calculated and grouped by Child-Turcotte-Pugh classification for cirrhosisThe hepatic volume of cirrhosis patients in Child A, B level was not reduced, but in Child C level itwhich reflects liver volume variations, correlates well with the liver function and progression of cirrhosis

Keywords: liver volume variation     cirrhosis     acute liver failure (ALF)    

Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations Article

Yanfei Chen, Jing Guo, Chunlei Chen, Ding Shi, Daiqiong Fang, Feng Ji, Lanjuan Li

Engineering 2021, Volume 7, Issue 4,   Pages 507-514 doi: 10.1016/j.eng.2020.04.014

Abstract: Several studies have indicated that the oral and gut microbiota may exhibit differences in patients with cirrhosisIn this study, the gastric mucosal microbiota of patients with liver cirrhosis and controls were analyzedIn H. pylori-negative subjects, gastric bacterial communities of healthy and cirrhosis cohortswere clustered into four clusters based on bacterial compositions: Cluster_1 and Cluster_2 (mostly cirrhosisthat the colonization of both H. pylori and non-H. pylori is influenced in liver cirrhosis

Keywords: Microbiome     Liver cirrhosis     Symptoms     Varices     Gastric endoscopy    

γδ T cells in liver diseases

Xuefu Wang, Zhigang Tian

Frontiers of Medicine 2018, Volume 12, Issue 3,   Pages 262-268 doi: 10.1007/s11684-017-0584-x

Abstract: roles in liver infection, non-alcoholic fatty liver disease, autoimmune hepatitis, liver fibrosis and cirrhosis

Keywords: γδT cells     liver infection     non-alcoholic fatty liver disease     autoimmune hepatitis     liver fibrosis and cirrhosis    

Current recommendations of managing HBV infection in preconception or pregnancy

James S. Park,Calvin Pan

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 158-165 doi: 10.1007/s11684-014-0340-4

Abstract:

Hepatitis B remains a leading cause of cirrhosis, hepatocellular carcinoma and liver transplantationmedication, antiviral therapy during the pregnancy should be limited to a selected group of patients with cirrhosis

Keywords: antiviral therapy     Caesarean section     cirrhosis     hepatitis B     immunoprophylaxis     mother-to-child transmission    

Direct acting antiviral-induced dynamic reduction of serum

Tung Huynh, Ke-Qin Hu

Frontiers of Medicine 2019, Volume 13, Issue 6,   Pages 658-666 doi: 10.1007/s11684-019-0707-7

Abstract: follow-up was 99 weeks (12–213); mean age, 57.8 years old; 52%, males; 79%, genotype (GT) 1; and 47%, cirrhosisOn multivariate analysis, baseline AFP>5.5 was associated with the presence of cirrhosis ( =0.001), co-existingPost-treatment week 24 AFP normalization was associated with the absence of cirrhosis ( = 0.003), Child–PughAFP elevation is common in patients with CHC and independently associated with NASH, cirrhosis, and GTPost-treatment week 24 AFP normalization is independently associated with the absence of cirrhosis, Child–Pugh

Keywords: chronic hepatitis C     α fetoprotein     direct acting antiviral treatment     cirrhosis    

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl

Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 398-408 doi: 10.1007/s11684-019-0689-5

Abstract: cirrhotic populations have been recently shown, but the long-term effects of UII receptor antagonist on the cirrhosisof urotensin II receptor (UT) antagonist palosuran on rats with carbon tetrachloride (CCl )-induced cirrhosisOur data indicate that long-term administration of palosuran can decrease PP in cirrhosis, which results

Keywords: portal hypertension     cirrhosis     urotensin II     palosuran     hepatic stellate cell    

Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells

Ling YANG, Rui ZHU, Qingjing ZHU, Dan DAN, Jin YE, Keshu XU, Xiaohua HOU

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 36-40 doi: 10.1007/s11684-009-0020-y

Abstract: This study aims to investigate the influence of β-elemene on the secretion of angiotensin II (ANG II) and the expression of angiotensin receptor type 1 (AT1R) in hepatic stellate cells (HSCs). , HSC-T6 were cultured for 24 hours and then treated with different doses of β-elemene (2.5, 5 and 10 mg/L). A control group was also set up. The secretion of ANG II in the supernatant was detected by radioimmunoassay. The mRNA expression of AT1R at 4, 12 and 24 h after treatment was detected by reverse transcription-polymerase chain reaction (RT-PCR), respectively. The protein expression of AT1R was detected by western blot. At the 4th h, the ANG II secretion in the supernatant was significantly inhibited by 10 mg/L β-elemene compared with the control group ( <0.05), while 5.0 mg/L and 2.5 mg/L β-elemene had no inhibitory effect on the secretion of ANG II ( >0.05). At the time point of the 12th h, the secretion of ANG II in the supernatant treated with 10 mg/L and 5.0 mg/L β-elemene was significantly lower than the control ( <0.01, <0.05). Following the treatment with 5.0 mg/L and 2.5 mg/L β-elemene for 24 h, significant inhibition of ANG II secretion was observed ( <0.05), but 10 mg/L β-elemene had no such effect. β-elemene significantly reduced the amount of AT1R mRNA in HSCs after the treatment for 4, 12, and 24 h in a dose-dependent manner. The expression of AT1R protein also decreased after the treatment with β-elemene for 24 h. β-elemene can inhibit the secretion of ANG II and the gene and protein expression of AT1R, which may be the mechanism by which β-elemene prevents the progress of hepatic fibrosis.

Keywords: liver cirrhosis     beta-elemene     hepatic stellate cells     angiotensin II     receptor     angiotensin     type 1    

Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis Article

Lin Wang, Yiqi Liu, Qixin Gu, Chi Zhang, Lei Xu, Lei Wang, Cuiying Chen, Xueen Liu, Hong Zhao, Hui Zhuang

Engineering 2023, Volume 26, Issue 7,   Pages 151-158 doi: 10.1016/j.eng.2023.03.008

Abstract: explore the role of serum N-glycomic-derived models in diagnosing significant liver fibrosis and cirrhosisserum N-glycan models in order to distinguish significant liver fibrosis (≥ F3) and cirrhosisIn distinguishing liver cirrhosis, the diagnostic AUROC curve of the serum N-glycan RF modelconstructed for distinguishing liver cirrhosis (≥ F5; RF-B model) was 0.97, and the coincidence-glycan models are promising markers for the differentiation of significant liver fibrosis and cirrhosis

Keywords: Liver fibrosis     Chronic hepatitis B     Serum N-glycan     N-glycan model     Alanine aminotransferase (ALT) level    

Title Author Date Type Operation

Correlation between viral load and liver cirrhosis in chronic hepatitis B patients

Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,

Journal Article

Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis

Jiangyi Zhu, Yongquan Shi, Xinmin Zhou, Zengshan Li, Xiaofeng Huang, Zheyi Han, Jianhong Wang, Ruian Wang, Jie Ding, Kaichun Wu, Ying Han, Daiming Fan

Journal Article

Effects of Decoction on plasma proteome in cirrhosis: preliminary experimental study with rats

LIU Jie, WANG Jiyao, WEI Liming, LU Ye, Jin Hong

Journal Article

Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated

Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang

Journal Article

Assessment of liver volume variation to evaluate liver function

Cong Tong, Xinsen Xu, Chang Liu, Tianzheng Zhang, Kai Qu

Journal Article

Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations

Yanfei Chen, Jing Guo, Chunlei Chen, Ding Shi, Daiqiong Fang, Feng Ji, Lanjuan Li

Journal Article

γδ T cells in liver diseases

Xuefu Wang, Zhigang Tian

Journal Article

Current recommendations of managing HBV infection in preconception or pregnancy

James S. Park,Calvin Pan

Journal Article

Direct acting antiviral-induced dynamic reduction of serum

Tung Huynh, Ke-Qin Hu

Journal Article

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl

Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang

Journal Article

Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells

Ling YANG, Rui ZHU, Qingjing ZHU, Dan DAN, Jin YE, Keshu XU, Xiaohua HOU

Journal Article

Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis

Lin Wang, Yiqi Liu, Qixin Gu, Chi Zhang, Lei Xu, Lei Wang, Cuiying Chen, Xueen Liu, Hong Zhao, Hui Zhuang

Journal Article